diabetic retinopathy glp 1 GLP-1 RA Weight Loss Drugs May Carry Untold Ocular Burden Key Facts GPs Should Know

Due to their popularity, these medications can often be in short supply

Samms RJ, Coghlan MP, Sloop KW (2020) How may GIP enhance the therapeutic efficacy of GLP-1

Data availability Details of the search strategy and list of identified articles can be found at Abbreviations BGM: Blood glucose monitoring CGM: Continuous glucose monitoring CSII: Continuous subcutaneous insulin infusion CVOT: Cardiovascular outcomes trial DKA: Diabetic ketoacidosis DPP-4i: Dipeptidyl peptidase-4 inhibitors DSMES: Diabetes self-management education and support ETD: Estimated treatment difference GIP: Glucose-dependent insulinotropic polypeptide GLP-1 RA: Glucagon-like peptide-1 receptor agonist(s) HF: Heart failure HHF: Hospitalisation for heart failure MACE: Major adverse cardiovascular events MNT: Medical nutrition therapy NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis SGLT1i: Sodiumglucose cotransporter-1 inhibitor SGLT2i: Sodiumglucose cotransporter-2 inhibitor(s) TZD: Thiazolidinedione UACR: Urinary albumin/creatinine ratio References Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS et al (2016) Shared decision making in endocrinology: present and future directions

The final coverage call After completing thorough clinical, affordability, and oversight evaluations, Capital Blue Cross decided to place oral Wegovy on the same formulary tier as the injectable version, reflecting comparable clinical value and similar expectations around appropriate use

Eli Lilly, the maker of the drug Mounjaro (Tirzepatide - LLY) , said it expects the medication could be approved by the U.S